Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial
Authors' conclusion
This randomized clinical trial among adults with osteogenesis imperfecta found that teriparatide plus zoledronic acid did not reduce fracture risk compared with standard care despite significantly increasing BMD
Study context
- Population
- Adults with clinical diagnosis of osteogenesis imperfecta at 27 referral centers; mean age 43.7 years, 53.9% female349 evaluable
- Participants
- 350 adults
- Comparison
- Teriparatide followed by zoledronic acid vs standard care
- Teriparatide plus zoledronic acidn = 176
- Standard caren = 174reference
- Primary endpoint
- Number of participants with imaging-proven incident fractures, adjudicated by reviewers blinded to allocation
Methodological detailsmulticenter, open-label, parallel-group, Conducted May 17, 2017 to March 21, 2025
- Multicenter
- Open-label
- Parallel-group
- Conducted May 17, 2017 to March 21, 2025
Primary result
As reported in the abstract
Incident fractures
Each group vs standard careAbsolute risk reduction, % (95% CI)
Teriparatide plus zoledronic acid
−1.57(−9.90% to 5.89%)
Each group vs standard careHazard ratio (95% CI)
Teriparatide plus zoledronic acid
0.97(0.68–1.38)
Secondary outcomes
Lumbar spine and total hip bone mineral density (BMD)
- Lumbar spine and total hip BMD increased significantly more with teriparatide plus zoledronic acid than standard care
Quality of life
- Several quality-of-life measures favored teriparatide plus zoledronic acid
Original publication
Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial. JAMA. Published 14 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →